Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers

Inclusion criteria

• Healthy adult male or females (women of non child bearing potential), 18-55 years of age (inclusive).
• Medically healthy with no clinically significant screening results.
• Non-vasectomized male subjects must agree to use birth control or abstain from sexual intercourse during and until 90 days beyond the last dose of study drug/placebo.
• Continuous non-smoker, at least 3 months prior to first dose and throughout the study.
• Understands the study procedures in the informed consent form, and be willing and able to comply with the protocol

Exclusion criteria

• Subject is mentally or legally incapacitated.
• History of any illness that, in the opinion of the PI, might confound the results of the study or poses an additional risk to the subjects by their participation in the study.
• History or presence of alcoholism or drug abuse within the past 2 years
• Female subject of childbearing potential.
• Blood donation or significant blood loss within 56 days prior to first dose.
• Plasma donation within 7 days prior to first dose.
• Participation in another clinical trial within 30 days prior to first dose.